Sustained workforce development for local health and research sectors as well as groundbreaking research are on the agenda.
Northern Health has joined forces with RMIT University to bolster local workforce development and accelerate the translation of cancer and nanoparticle diagnostic research into clinical practice.
Initially prioritising trials investigating novel treatments or therapeutic interventions for cancer, blood disorders and chronic diseases, the clinical translational research partnership will offer a number of Masters and PhD positions to recruit a “highly skilled talent pool” of students interested in working across the research and healthcare sectors, the announcement said.
Research undertaken through the new partnership would also build on close collaboration with the pharmaceutical industry to support the translation of research findings to accessible treatments and therapies for patients.
According to Associate Professor Prahlad Ho, chair of Northern Health’s research executive committee, the partnership would offer a “pipeline” to ensure novel therapies and diagnostic approaches reached patients faster.
“Our clinical translational research partnership is critical to improve research capabilities across northern Melbourne, including delivery of innovative clinical trial capabilities as well as novel biomarkers in our multicultural population,” Associate Professor Ho said.
“Northern Health’s partnership with RMIT will allow a pipeline for the rapid and effective translation of key technological advances into clinical use.”
